Patents, net

12 Months Ended

Jun. 30, 2022

5. Patents, net

Patents, net consisted of the following (rounded to nearest thousand):

	Useful life (years)		June 30, 2022			June 30, 2021
Purchased Patent Rights- Brilacidin and related compounds		14	$	4,082,000		$	4,082,000
Purchased Patent Rights-Anti-microbial- surfactants and related compounds		12		144,000			144,000
Patents – Brilacidin, and other compounds		17		1,146,000			1,280,000
Total patents cost				5,372,000			5,506,000
Less: Accumulated amortization				(3,060,000	)		(2,752,000	)
Patents, net			$	2,312,000		$	2,754,000

The patents are amortized on a straight-line basis over the useful lives of the assets, determined to be 12-17 years from the date of acquisition.

Amortization expense for the years ended June 30, 2022 and 2021 was approximately $382,000 and $378,000, respectively. During the fiscal years ended June 30, 2022 and 2021, the Company has written off the patent costs relating to Kevetrin of approximately $141,000 and $0, respectively and included these in general and administrative expenses.

At June 30, 2022, the future amortization period for all patents was approximately 12 years to 17 years. Future estimated amortization expenses are approximately $371,000 for each year from 2023 to 2025, $361,000 for the year ending June 30, 2026 and a total of $838,000 for the year ending June 30, 2027 and thereafter.